Literature DB >> 18656240

Reappraisal of T3N0/NxM0 renal cell carcinoma: significance of extent of fat invasion, renal vein invasion, and adrenal invasion.

Soo Jin Jung1, Jae Y Ro, Luan D Truong, Alberto G Ayala, Steven S Shen.   

Abstract

T3 renal cell carcinoma (RCC) is a heterogeneous group of tumors that are substaged based on perirenal or sinus fat invasion, adrenal invasion, and renal vein invasion. To evaluate whether the extent of fat invasion (minimal versus extensive) and direct adrenal gland invasion, renal vein invasion with or without concurrent fat invasion has a similar prognosis, we retrospectively reviewed 198 T3N0/NxM0 RCCs in a single academic tertiary hospital. Fat invasion was subdivided as minimal (< or =5 mm into the fat) or extensive (>5 mm) invasion. Direct adrenal invasion was defined as contiguous involvement of ipsilateral adrenal gland. Among the 198 T3 RCCs, minimal and extensive fat invasions were identified in 57 and 61 cases, respectively; renal vein invasion and direct adrenal invasion were seen in 66 and 14 cases. The patients' average age was 62.9 years, and 145 patients were male and 53 were females. The 2-year and 5-year survival rates were 85% and 56% for minimal fat invasion, 76% and 70% for extensive fat invasion, and 55% and 32% for renal vein invasion, respectively. There was no difference of survival in patients with T3b (renal vein invasion) RCC stratified by presence or absence of concurrent fat invasion. The 2-year and 5-year survival rates for adrenal invasion were 31% and 21%, respectively, which was significantly worse than that of fat or renal vein invasion. Multivariate analysis showed that nuclear grade, sarcomatoid differentiation, and subgrouping of pT3 RCC (fat invasion, renal vein invasion, and adrenal invasion) remained independent predictors of patient's overall survival. In conclusion, our study shows that T3 RCCs with minimal or extensive perinephric fat invasion has a similar prognosis and is significantly more favorable than that of renal vein invasion regardless of presence or absence of concurrent fat invasion. In contrast, tumors with adrenal gland invasion carry a far worse prognosis than perinephric fat or renal vein invasion and thus supporting a separate stage category.

Entities:  

Mesh:

Year:  2008        PMID: 18656240     DOI: 10.1016/j.humpath.2008.04.011

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Prognostic impact of muscular venous branch invasion in localized renal cell carcinoma cases.

Authors:  Andrew Feifer; Caroline Savage; Heidi Rayala; William Lowrance; Geoffrey Gotto; Preston Sprenkle; Amit Gupta; Jennifer Taylor; Melanie Bernstein; Adebowale Adeniran; Satish K Tickoo; Victor E Reuter; Paul Russo
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

2.  Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases.

Authors:  Ankur R Sangoi; Mika Fujiwara; Robert B West; Kelli D Montgomery; Joseph V Bonventre; John P Higgins; Robert V Rouse; Neriman Gokden; Jesse K McKenney
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

3.  Prognostic Evaluation of the Site of Invasion in Pathological Stage T3a Renal Cell Carcinoma.

Authors:  Gu-Shun Lai; Jian-Ri Li; Shian-Shiang Wang; Chuan-Shu Chen; Chun-Kuang Yang; Sheng-Chun Hung; Chen-Li Cheng; Yen-Chuan Ou; Kun-Yuan Chiu
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

4.  Application of the revised Tumour Node Metastasis (TNM) staging system of clear cell renal cell carcinoma in eastern China: advantages and limitations.

Authors:  Chao Qin; Li-Jiang Sun; Li Cui; Qiang Cao; Jian Zhu; Pu Li; Gui-Ming Zhang; Xin Mao; Peng-Fei Shao; Mei-Lin Wang; Zheng-Dong Zhang; Min Gu; Wei Zhang; Chang-Jun Yin
Journal:  Asian J Androl       Date:  2013-04-08       Impact factor: 3.285

5.  Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma.

Authors:  Jong Jin Oh; Jung Keun Lee; Byung Do Song; Hakmin Lee; Sangchul Lee; Seok-Soo Byun; Sang Eun Lee; Sung Kyu Hong
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.